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CSF AVP level was correlated with ICP (r= 0.46, P<0.05), but
no statistically significant correlation was found between
plasma AVP, CSF AVP and initial GCS (r= -0.29, P>0.05 and
r= -0.32, P>0.05, respectively). The ICP (mm Hg) in tSAH
patients was elevated and higher in GCS≤8 group than in
GCS>8 group (25.9±9.7 vs 17.6±5.2, P<0.05).
Conclusion:    Our research suggests that AVP is corre-
lated with the severity of tSAH, and may be involved in the
pathophysiological process of brain damage in the early
stage after tSAH. It seems that compared with the plasma
AVP concentration, CSF AVP is more related to the severity
of tSAH.
Key words:    Arginine vasopressin; Subarachnoid
hemorrhage, traumatic; Glasgow coma scale; Intracra-
nial pressure
【Abstract】Objective:    To investigate the changes
and effects of arginine vasopressin (AVP) in patients with
acute traumatic subarachnoid hemorrhage (tSAH).
Methods:    The plasma and cerebrospinal fluid (CSF)
level of AVP, and intracranial pressure (ICP) were measured
in a total of 21 patients within 24 hours after tSAH. The
neurological status of the patients was evaluated by
Glasgow Coma Scale (GCS). Correlation between AVP and
ICP, GCS was analyzed respectively. Meanwhile, 18 healthy
volunteers were recruited as control group.
Results:    Compared with control group, the levels (pg/ml)
of AVP in plasma and CSF (χ±s) in tSAH group were signifi-
cantly increased within 24 hours (38.72±24.71 vs 4.54 ±1.38
and 34.61±21.43 vs 4.13±1.26, P<0.01), and was remarkably
higher in GCS≤8 group than GCS>8 group (50.96±36.81 vs
25.26±12.87 and 44.68±31.72 vs 23.53±10.94, P<0.05). The
Subarachnoid hemorrhage (SAH), a frequent andfatal neurosurgical emergency,1 falls into twogeneral categories: traumatic and spontaneous.
Spontaneous SAH (sSAH) has been studied in detail
in neurosurgery and many researches on its manage-
ment have been carried out. Traumatic SAH (tSAH) is
more common than sSAH, but less attention has been
paid by researchers, since it is frequently associated
with other primary gross intracranial pathology in most
cases. Arginine vasopressin (AVP), known as a
neurotransmitter, is a cyclic nonapeptide synthesized
in the hypothalamus and released into the systemic
circulation through the posterior pituitary gland.2 AVP
has been found elevated in the plasma of patients with
traumatic brain injury (TBI).3 Our previous study also
found an increased AVP concentration in the plasma of
TBI patients.4 Experimental evidence demonstrated that
AVP plays an important role in the pathological progress
of TBI,5 which is the leading cause of SAH. Therefore, it
is necessary to clarify the change of AVP level in pa-
tients with tSAH. Our present study was focused on
the change of AVP level in plasma and CSF in patients
with tSAH, in order to investigate the possible relation-
ship between AVP and the neurological status of pa-
tients with tSAH.
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METHODS
All the procedures in this study were in accordance
with the Ethics Committee of Zhejiang University. Pa-
tients from January 2004 to June 2006 were screened
according to specific inclusion and exclusion criteria.
Clinical data
A total of 21 patients with acute tSAH (7 females
and 14 males, aged from 19 to 62 years with a mean
age of 34.63 years) were enrolled according to the following
criteria: (1) hospitalization within 24 hours after brain
injuries; (2) evidence of meningeal irritation (neck
stiffness)and SAH approved by spinal tap and CT; (3)
without concomitant severe injuries; (4) no severe un-
derlying diseases prior to injuries; and (5) without any
dysfunction of heart, lung, kidney or other important
organs. The enrolled patients included 9 cases of cere-
bral contusion, 4 epidural hematoma, 3 subdural
hematoma, 2 intracerebral haematoma and 3 without
extra injury in the brain parenchyma by CT scanning.
All patients in tSAH group were scanned with cranial
CT and performed the spinal tap to authenticate the
clinical diagnosis. Spinal tap was performed 8 hours
(the time of one CSF circulation) after the brain injuries.
Glasgow Coma Scale (GCS) scores were assessed
when the patients were admitted. There were 10 pa-
tients with GCS>8 (the moderate injury group) and 11
patients with GCS≤8 (the severe injury group). The
18 volunteers (6 females and 12 males, aged from 22
to 58 years, with a mean age of 35.47 years) in the
control group had no abnormal findings on a clinical or
laboratory base.
Sample collection and testing methods
Venous blood samples (2 ml) were collected in the
morning at rest from the healthy volunteers and from
the tSAH patients within 24 hours after traumatic brain
injury (TBI). CSF (2 ml) was collected within 8 to 24
hours with spinal tap after TBI, meanwhile, ICP was
tested. All the samples were put in pre-cooled centri-
fuge tubes containing 50 µl of 0.3 mol/L ethylene di-
amine tetraacetic acid sodium (EDTA-Na) and 5×105 U
of trasylol, then centrifuged at 4°C, 3000 r/min for 10
minutes. All samples were stored at -70°C until being
assayed. The levels of AVP were determined by radio-
immunoassay (RIA) after extraction and concentration
using SEP-PAK cartridges. The AVP level was mea-
sured in Hangzhou Radioimmunologic Center. Radio-
immunoassay reagent kits were supplied by DSL
Company, USA. The detecting instrument, γ-counting
meter, was made by DPC Company, USA.All the
samples were marked and measured with double blind
method. All tSAH patients were treated with traditional
therapy, including reducing the elevated intracranial
pressure, administrating drugs, maintaining water and
electrolytes homeostasis, and operation if necessary.
Statistical analysis
All the data were expressed as χ ± s. Differences
between groups were analyzed using the two-tailed
Student’s t-test. Correlations between variables were
assessed by the Spearman test. P<0.05 was consid-
ered statistically significant. All the offline analysis was
performed by SPSS 13.0 software package (SPSS,
Chicago, USA).
RESULTS
Correlation between plasma AVP and CSF AVP in
patients with acute tSAH
Within 24 hours after tSAH, the mean AVP levels in
plasma and CSF in tSAH group were significantly higher
than those in control group (P<0.01). There was no sig-
nificant difference between the plasma AVP and CSF
AVP (P>0.01, Table 1). A positive correlation was found
between the plasma and CSF AVP (r=0.661, P<0.05).
Relationship between plasma AVP, CSF AVP and GCS
There were 11 patients with severe brain injury (initial
GCS≤8) and 10 patients with mild or moderate brain
injury (initial GCS>8). The mean AVP levels in plasma
and CSF in GCS≤8 group were significantly higher
than those in GCS>8 group (P<0.05, Table 2). However,
No statistically significant correlation was found between
plasma AVP, CSF AVP and the initial GCS (r =-0.29,
P>0.05 and r =-0.32, P>0.05, respectively, Table 3).
Relationship between plasma AVP, CSF AVP and
ICP
The mean ICP in all patients with tSAH was (21.9
±8.5) mm Hg, including 17 patients with intracranial
hypertension (more than 20 mm Hg). ICP was signifi-
cantly higher in GCS≤8 group than in GCS>8 group
(P<0.05, Table 2). Correlation between CSF AVP and ICP
was statistically significant (r= 0.46, P<0.05), while no
obvious correlation was found between plasma AVP
and ICP (r =0.34, P>0.05, Table 3).
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patients, which suggested a severe injury in the head.9,10
Our findings also showed that AVP levels in plasma
and CSF increased in the early stage of tSAH.
Vasospasm is one of the most critical complications,
which contributes to the high morbidity and mortality
associated with SAH, as well as the bad outcomes.11
Other study found that the initial GCS score was in-
versely related to the development of post-traumatic
vasospasm but in most cases the period of vasospasm
was short and clinical deterioration was rare.12 The com-
plex mechanism of this arterial narrowing is not yet
fully understood.13 The existence of extrahypophyseal
vasopressinergic pathways within the brain has been
found and may allow for independent release and func-
tioning of central AVP vs systemic AVP.14 AVP caused
vasoconstriction and intracisternal injection of AVP deter-
mined acute vasospasm with a time course similar to
the phenomena that seen in normal rats after SAH.15, 16
But other research did not support the hypothesis that
vasospasm and delayed ischemia were responsible for
the poor outcome in tSAH patients.17 In our study, in-
verse correlation between plasma AVP, CSF AVP and
GCS score was not statistically significant and no sig-
nificant correlation between CSF AVP level and GCS
score was found. The limitation was that the degree of
cerebral vasospasm was not explored. So it could not
be confirmed that AVP is a specific biomarker or plays
a key role by aggravating cerebral vasospasm in the
pathophysiology of tSAH. Further researches are
needed to explore the role of AVP and the relationship
between AVP and cerebral vasospasm in the patients
with tSAH.
Increase of AVP concentration in the early stage of
SAH is of pathogenetic significance in the development
of brain edema.7 The high plasma AVP level in tSAH
may promote the formation and development of brain
edema and secondary cerebral infarction. ICP monitor-
ing has become common practice in the management
of many neurologic disorders.18 ICP data are also strong
predictors of clinical outcome. Patients with normal ICP
showed the best prognosis, whereas patients with in-
creased but controllable ICP did worse and patients
with uncontrollable ICP did the worst. In our study, most
cases (17/21) had intracranial hypertension. ICP in
GCS>8 group was higher than that in GCS≤8 group.
A statistically significant correlation was found between
the CSF AVP level and ICP, but no remarkable correla-
Table 1. Comparison between plasma AVP and CSF AVP
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Table 3. Correlation between plasma AVP, CSF AVP and
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In this study, we found that the AVP levels in plasma
and CSF were significantly increased in tSAH patients,
and AVP in GCS≤ 8 group was significantly higher
than that in GCS>8 group, although neither plasma AVP
nor CSF AVP had statistically significant correlation
with GCS. The increase of ICP was more evident in
GCS≤8 group, together with high correlationship be-
tween CSF AVP and ICP in tSAH patients. But there
was no significant correlation between the plasma AVP
and ICP. These data indicated the pathophysiological
role of AVP in tSAH.
AVP, especially AVP secreted by the hypothalamo-
neurohypophyseal system, might act as a neurohu-
moral factor and is involved in brain injury paradigms,
including SAH6, 7 and TBI8. Our early study found that
AVP level was elevated in serum 24 hours after TBI and
higher in patients with severe injuries than in patients
with moderate injuries.4 GCS could be used as an early
predictor for tSAH patients. The lower score of GCS at
admission adumbrated a poorer prognosis in tSAH
Table 2. Comparison between plasma AVP, CSF AVP
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  <0.05
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tion was found between the plasma AVP level and ICP,
although there was significant correlation between the
plasma AVP and CSF AVP levels. The elevated AVP
level, especially the CSF AVP level, may indicate the
severe brain damage and deterioration of the conditions.
The cerebral AVP may play an important role in the
progress of intracranial hypertension and brain edema.
In conclusion, our preliminary study found that
plasma AVP levels are elevated after tSAH. The increase
of plasma AVP and CSF AVP concentrations in the
early stage is related to the severity of brain injury. AVP
may play an important role in the pathophysiological
process of cerebral vasospasm, brain edema and sec-
ondary cerebral infarction. Further study on the precise
mechanisms of the role of AVP and clinical significance
of agents that attenuate its release following tSAH is
required.
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